HOME     NEWS    CONTACT

News

InnoAsia 2013

October 18th, 2013

 

It is our pleasure to be a supporting organisation of InnoAsia again.  The event, organised by Hong Kong Science & Technology Parks Corporation (HKSTPC) with The Hong Kong University of Science & Technology as strategic partner, is a four day event comprising a main conference, chairmen’s forum, six tech forums, investment conference, two workshops and venture capital/angel matching SPARC Forums to be held from 4 to 7 December 2013 at Hong Kong Convention & Exhibition Centre (HKCEC).

Focusing on the theme “Towards a smart green city agenda”, this event will bring together top business leaders, renowned industry professionals and academia to share their experience and insights on energy optimisationrenewable resourcescarbon footprints reductiongreen architecture, advanced robotics, healthcare and transportation system.

For details of the programme agenda, please visit: www.innoasia.net.

InnoAsia 2012

October 10th, 2012

It is our pleasure to be a supporting organisation of InnoAsia 2012.  The event, organised by Hong Kong Science & Technology Parks Corporation with The Chinese University of Hong Kong as strategic partner, is a four day event comprising a main conference, chairmen’s forum, four tech forums, investment conference, two workshops and venture capital/angel matching SPARC Forums to be held 13-16 November 2012 at the Hong Kong Science Park.

Focusing on the theme “Innovations for Green and Healthy Living”, this event will bring together top business leaders, renowned industry professionals and academia to share their experience and insights on business and technology opportunities in energy efficiency and management, cleantech, renewable technologies and sustainability solutions.

For details of the programme agenda, please visit: www.innoasia.net.

The University of Western Ontario (UWO) Signed an Agreement with Xiamen Bioway Biotech Co., Ltd for Creation of a Joint Venture

May 1st, 2012

In early 2011, the University of Western Ontario and Xiamen Bioway Biotech Co., Ltd reached a cooperation agreement on “Small Molecules, Peptide, and Nucleotide Therapeutics for Promoting Nerve Regeneration Following Neurotrauma”. Spinal cord injury (SCI) is a personally catastrophic event that often results in disability and lifelong institutional care requirements. This technology uses small molecules, peptide, and nucleotide to promote nerve regeneration following neurotrauma. It is expected the said technology can repair damages in the spectrum of central nervous system disorders including Traumatic Brain Injury, stroke, and response to neurodegenerative disease.

After more than ten years of hard work, Xiamen Bioway Biotech Co., Ltd has developed as one of the leading enterprises in Chinese biological industry with a high international competitiveness. The company has attached great importance to R&D, and formed a consummate bio-medicine research centre with a group of excellent researchers.

Further to the current cooperation and relations between UWO and the company, the two sides reached an agreement to create a joint venture. A new company, NewCo, will be formed as a result of the joint venture. It is expected the establishment of Newco will bring further cooperation between the both parties.

Mr. Ren, the vice president of Xiamen Bioway Biotech Co., Ltd, said he was very glad the to form a joint venture with UWO and he was looking forward to bringing new product of the technology to the product market and helping patients to conquer their diseases.

The University of Western Ontario (UWO) Signed an Intellectual Property Agreement with Targetpharma Laboratories (Jiangsu), The State Key Laboratory of Pharmaceutical Biotechnology

May 1st, 2012

“The Opening Ceremony of China Technology Transfer Centre of The University of Western Ontario, Canada and Project Signing Ceremony”, was held on April 26th, Dr Janice Deakin (Vice President and Provost of UWO) signed an Intellectual Property Agreement which is “Small Cyclic Peptide Therapeutics with Anti-Microbial and Pro-healing Properties” with Prof. Hua Zichun (the director of The State Key Laboratory of Pharmaceutical Biotechnology).

Prof. Hua has been engaging in the research of peptide drugs, such as protein engineering, gene engineering, protein structure and the integration of cell apoptosis signaling pathway. He has obtained ten Chinese invention patents and one patent license authorized by the United States. Among the obtained patents, five patents have got application and two patents have already been commercialized to enterprises to develop biological drugs. This Laboratory has formed a high-talented research group and committed to uncovering the pathophysiological mechanisms of diseases that severely threaten the health of human beings, including cardiovascular disorders, immunological as well as metabolic diseases.

“Small Cyclic Peptide Therapeutics with Anti-Microbial and Pro-healing Properties”, the technology transferred by UWO, is a new treatment to human pathogens. The small cyclic peptide bases upon naturally occurring human protein, so it’s almost non-toxic. It has been extensively optimized to enhance its ease of production, stability, potency, and retention of both healing and anti-microbial properties. In addition to its fast and potent broad spectrum anti-fungal/anti-bacterial properties, the compound demonstrates strong capacity to augment wound healing and promote skin maturation following topical injury suggesting a biphasic therapeutic activity.

The cooperation between UWO and the lab will work on novel antifungals and antimicrobials that are non-toxic to humans but are highly potent against human pathogens.

The University of Western Ontario Signed an Intellectual Property Agreement with Kunshan RNAi Institute Co., Ltd.

May 1st, 2012

On April 26th, 2012, “the Opening Ceremony of China Technology Transfer Centre of The University of Western Ontario, Canada and Project Signing Ceremony” was held in Nanjing New-Town Sci-Tech Park. At the ceremony an Intellectual Property Agreement, “MicroRNA as a Therapeutic Agent in Diabetic Retinopathy and Other Diabetic Complications”, was signed between the University of Western Ontario(UWO) and Kunshan RNAi Institute Co., Ltd.

Diabetic retinopathy (DR) is a serious complication of diabetes and the leading cause of blindness in diabetics. Currently DR can only be managed with surgical treatments and life style changes. A leading team of scientists at UWO has found several naturally occurring miRNAs. Administration of the identified miRNAs induces a therapeutic response by blocking glucose induced up regulation of VEGF and increases angiogenesis. Their finding provides a means to use naturally occurring molecules to inhibit VEGF which leads to significantly lower toxicity potential compared to other pharmacological approaches to inhibit VEGF. The technology will be used in the field of diagnostic and treatment of human diabetic retinopathy, diabetic nephropathy, or diabetic large vessels disease.

Kunshan RNAi Institute is an important driving force to the innovation and development of the biological medicine industry in Kunshan. This Institute contributes in gathering resources for RNAi R&D in China, such as new technology and equipment. It also contributes in bringing in the best research team for further R&D of RNAi, as well as supporting some RNAi projects.

The cooperation between UWO and Kunshan RNAi Institute is expected to bring breakthroughs to the treatment of diabetic retinopathy and more commercial opportunities.

 

China Technology Transfer Centre of The University of Western Ontario, WORLDiscoveries Asia Limited – Nanjing, Settled in Nanjing New Town Sci-Tech Park

April 30th, 2012

On April 26th, 2012, “the Opening Ceremony of China Technology Transfer Centre of The University of Western Ontario, Canada and Project Signing Ceremony” was held in Nanjing New-Town Sci-Tech Park. It marked the establishment of The Western University’s  first overseas technology transfer operation , which  was inaugurated by Hon. Joe Fontana, Mayor of London, Canada and Mr. Sumin Cao, Deputy Director-General of Science and Technology Department of Jiangsu.

The Centre will become a gateway for innovative and breakthrough Canadian technologies to be further developed and commercialized in China. This ceremony was presided over by Mr. Yangwei Zhao, Director of International Cooperation of Science and Technology Department of Jiangsu Province. Several foreign dignitaries also attended the event including Mr. Eric Pelletier (Canadian consul general in Shanghai), Hon. Joe Fontana (Mayor of London, Canada)  Dr Janice Deakin (Vice President and Provost of The University), and Dr. Michael Strong (Dean of Schulich School of Medicine and Dentistry).There were a total of 19 representatives from Canadian Government and The Western University. The event was also attended by several Nanjing municipal leaders and representatives of related institutes and enterprises in China including Mr. Ming Chen (Counselor of International Cooperation of Chinese Science and Technology Ministry), Mr. Sumin Cao (Deputy Director-General of Science and Technology Department of Jiangsu Province), Mr. Qun Luo (Deputy Mayor of Nanjing City),  and Mr. Jun Zhang (District Governer  of Jianye District of Nanjing City). At the ceremony The University signed three Intellectual Property Agreement with Kunshan RNAi Institute Co., Ltd., Targetpharma Laboratories (Jiangsu) and Xiamen Bioway Biotech Co., Ltd, respectively.

About WORLDiscoveries

WORLDiscoveries is one of Canada’s top five technology transfer institutions. It is one of the founding members of the technology transfer consortium (C4) of Southwestern Ontario, which covers more than 10 universities and research institutes that have a research budget of 1 billion CAD (6.5 billion RMB) and more than 10,000 faculty members. WORLDiscoveries had started to research the Chinese market since 2007 in order to promote research exchange between The University and China and to seek collaboration partners to commercialize research from Ontario in the Chinese market. Since 2009 team members from WORLDiscoveries have visited China many times and established a great relationship with Science and Technology Department of Jiangsu Province and its Exchange Centre.

WORLDiscoveries is maintaining close ties with many Chinese industry players including, but not limited to, Taizhou medical city, Chanzhou biomedical industrial park and Suzhou high-tech zone. In late 2011, with a plan to expand its operations in Asia, WORLDiscoveries decided to set up a branch institution in Nanjing. After careful consideration, Nanjing New Town Sci-Tech Park was selected to be the home to WORLDiscoveries’ first China Technology Transfer Centre. Western  is the first  Canadian and North American University to set up a permanent tech-transfer centre in China. This development is expected to be be mutually beneficial for Ontario and Jiangsu and will bring advanced technologies for enterprises in Jiangsu Province to enhance their R&D pipeline increase investment returns. Meanwhile, the set-up of this centre is going to be a model for other North American technology transfer institutions to enter and grow in Chinese market, and thereby, lead the science and technology cooperation between the two markets.

 

WORLDiscoveries ASIA Website Launch

April 24th, 2012

We are happy to announce the official launch of our website. Please take the time to peruse our website for information about our organization and the services we offer. If you have any questions, please connect with a member of our team or contact us.